4-溴甲基苯并噁二唑 | 32863-30-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶二唑类
• 中文名称: 4-溴甲基苯并噁二唑
• 中文别名: 4-溴甲基-2,1,3-苯并恶二唑
• 英文名称: 4-bromomethylbenzofurazan
• 英文别名: 4-(bromomethyl)benzo[c][1,2,5]oxadiazole；4-(bromomethyl)-2,1,3-benzoxadiazole；5-bromomethylbenz[1,2,5]oxadiazole；4-bromomethyl-benzo[1,2,5]oxadiazole
• CAS: 32863-30-2
• 化学式: C₇H₅BrN₂O
• mdl: MFCD00515010
• 分子量: 213.033
• InChiKey: OFUZQEBZOGPUBJ-UHFFFAOYSA-N

物化性质

• 熔点：
  77 °C
• 沸点：
  283.5℃
• 密度：
  1.742
• 闪点：
  125.3℃

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.142
• 拓扑面积：
  38.9
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26,S37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2934999090
• 危险性防范说明：
  P261,P280,P301+P312,P302+P352,P305+P351+P338
• 危险性描述：
  H302
• 储存条件：
  存储条件为2-8°C，并需保存在惰性气体中。

SDS

Name:	4-(Bromomethyl)-2 1 3-benzoxadiazole Material Safety Data Sheet
Synonym:	None Known
CAS:	32863-30-2

Section 1 - Chemical Product MSDS Name:4-(Bromomethyl)-2 1 3-benzoxadiazole Material Safety Data Sheet
Synonym:None Known

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
32863-30-2	4-(Bromomethyl)-2,1,3-benzoxadiazole	95+	unlisted

Hazard Symbols: C
Risk Phrases: 34

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Causes burns.
Potential Health Effects
Eye:
Causes eye burns.
Skin:
Causes skin irritation. Causes skin burns. May be harmful if absorbed through the skin.
Ingestion:
Causes gastrointestinal tract burns.
Inhalation:
Causes chemical burns to the respiratory tract.
Chronic:
Chronic exposure may cause effects similar to those of acute exposure.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
In case of contact, immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Get medical aid immediately. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water.
Inhalation:
Get medical aid immediately. Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Do NOT use mouth-to-mouth resuscitation.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or appropriate foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Clean up spills immediately, observing precautions in the Protective Equipment section. Sweep up or absorb material, then place into a suitable clean, dry, closed container for disposal. Avoid generating dusty conditions. Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Minimize dust generation and accumulation. Do not breathe dust, vapor, mist, or gas. Do not get in eyes, on skin, or on clothing.
Keep container tightly closed. Do not ingest or inhale. Use with adequate ventilation. Wash clothing before reuse. Discard contaminated shoes.
Storage:
Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances. Store under an inert atmosphere.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 32863-30-2: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
A respiratory protection program that meets OSHA's 29 CFR 1910.134 and ANSI Z88.2 requirements or European Standard EN 149 must be followed whenever workplace conditions warrant respirator use.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: pale yellow
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 77-79 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C7H5BrN2O
Molecular Weight: 213.033

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable at room temperature in closed containers under normal storage and handling conditions.
Conditions to Avoid:
Dust generation.
Incompatibilities with Other Materials:
Oxidizing agents, reducing agents, acids, bases.
Hazardous Decomposition Products:
Carbon monoxide, oxides of nitrogen, carbon dioxide, hydrogen bromide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 32863-30-2 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
4-(Bromomethyl)-2,1,3-benzoxadiazole - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION
Ecotoxicity:
Fish: Pseudomonas putida:

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: CORROSIVE SOLID, ORGANIC, N.O.S.
Hazard Class: 8
UN Number: 3261
Packing Group: III
IMO
Shipping Name: CORROSIVE SOLID, ORGANIC, N.O.S.
Hazard Class: 8
UN Number: 3261
Packing Group: III
RID/ADR
Shipping Name: CORROSIVE SOLID, ORGANIC, N.O.S.
Hazard Class: 8
UN Number: 3261
Packing group: III

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: C
Risk Phrases:
R 34 Causes burns.
Safety Phrases:
S 6 Keep under nitrogen.
S 22 Do not breathe dust.
S 24/25 Avoid contact with skin and eyes.
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
WGK (Water Danger/Protection)
CAS# 32863-30-2: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 32863-30-2 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 32863-30-2 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-溴甲基苯并噁二唑 在 N-溴代丁二酰亚胺(NBS) 、 sodium 、 三乙胺 、 过氧化苯甲酰 作用下， 以 四氯化碳 、 乙醇 、 二氯甲烷 为溶剂， 反应 14.5h， 生成 达罗地平
  参考文献：
  名称：

  Synthesis of asymmetric 4-aryl-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylates with vasodilating and antihypertensive activities.

  摘要：

  合成了非对称的4-芳基-1,4-二氢-2,6-二甲基-3,5-吡啶二羧酸酯，其中含有2-乙烯二氧丙基、2-氧丙基或环丙基甲基作为酯基，以及相关衍生物，并进行了在麻醉开放胸腔犬中的扩血管活性及在意识清醒的自发性高血压大鼠中的抗高血压活性测试。环丙基甲基甲基1,4-二氢-2,6-二甲基-4-(3-硝基苯基)-3,5-吡啶二羧酸酯（5f，MPC-2101）和甲基2-氧丙基1,4-二氢-2,6-二甲基-4-(2-硝基苯基)-3,5-吡啶二羧酸酯（8i，MPC-1304）分别表现出强效的脑扩血管和抗高血压活性。在3.0 μg/kg的静脉给药后，5f对脊椎血流的最大增加为221.4%，而硝苯地平和尼卡地平氯化物分别为187.0%和166.3%。8i在0.3和1.0 mg/kg口服给药后的收缩压最大下降分别为42.2和54.0 mmHg，而硝苯地平、尼卡地平和肼苯噻啶氯化物在3.0 mg/kg时的最大下降分别为23.3、16.8和24.5 mmHg。5f和8i的显著扩血管和抗高血压效果持续时间比硝苯地平和尼卡地平更长。

  DOI：

  10.1248/cpb.34.1589
• 作为产物：
  描述：

  7 - 甲基-1H -苯并[D]咪唑 在 四氯化碳 、 N-溴代丁二酰亚胺(NBS) 、 过氧化苯甲酰 作用下， 以77.6%的产率得到4-溴甲基苯并噁二唑
  参考文献：
  名称：

  一种制备含有苯并呋咱环类抗高血压药物的合 成方法

  摘要：

  本发明涉及一种制备含有呋咱环类抗高血压药物的合成方法，以4-甲基苯并呋咱为原料，经溴化、氧化反应制备重要中间体4-甲酰基苯并呋咱、再与乙酰乙酸酯发生Hantzsch反应制备目标化合物。本发明与其它工艺相比，它具有反应条件温和，操作简单，高效，收率高等特点，具有一定的工业化生产前景。

  公开号：

  CN102285978B

文献信息

• [EN] DIHYDROTHIENO[3,2-b]PYRIDINE COMPOUNDS<br/>[FR] COMPOSÉS DE DIHYDROTHIÉNO [3,2-B] PYRIDINE
  申请人：IDEAYA BIOSCIENCES INC

  公开号：WO2019067442A1

  公开（公告）日：2019-04-04

  Compounds are provided having Formula (I): wherein R, R1, Cyc and A have the meanings provided herein. The compounds have utility in the treatment of diseases, either alone or in combination with other agents.

  提供具有公式(I)的化合物：其中R、R1、Cyc和A具有本文件中提供的含义。这些化合物可用于治疗疾病，可以单独使用，也可以与其他药剂联合使用。
• 联苯类化合物及其制备方法和医药用途
  申请人：中国药科大学

  公开号：CN111909108B

  公开（公告）日：2023-05-02

  本发明公开了联苯类化合物及其制备方法和医药用途，该联苯类化合物结构如式(I)或式(II)所示，本发明的联苯类化合物或其药学上可接受的盐、互变异构体、内消旋体、外消旋体、立体异构体、代谢产物、代谢前体、前药或溶剂化物是PD‑L1抑制剂，对PD‑1和PD‑L1蛋白‑蛋白相互作用具有显著的抑制作用，因而可应用于制备PD‑L1抑制剂，并应用于制备预防或治疗肿瘤、自身免疫性疾病、器官移植排斥、感染性疾病和炎症性疾病的免疫调节剂类药物；
• Syntheses, Biological Evaluations, and Mechanistic Studies of Benzo[<i>c</i>][1,2,5]oxadiazole Derivatives as Potent PD-L1 Inhibitors with <i>In Vivo</i> Antitumor Activity
  作者：Liu Liu、Zhiying Yao、Shijun Wang、Tao Xie、Guoqing Wu、Honghan Zhang、Pu Zhang、Yaojun Wu、Haoliang Yuan、Hongbin Sun

  DOI：10.1021/acs.jmedchem.1c00392

  日期：2021.6.24

  A series of novel benzo[c][1,2,5]oxadiazole derivatives were designed, synthesized, and biologically evaluated as inhibitors of PD-L1. Among them, compound L7 exhibited 1.8 nM IC50 value in a homogeneous time-resolved fluorescence (HTRF) assay, which was 20-fold more potent than the lead compound BMS-1016. In the surface plasmon resonance (SPR) assay, L7 bound to human PD-L1 (hPD-L1) with a KD value

  设计、合成了一系列新型苯并[ c ][1,2,5]恶二唑衍生物，并对其作为PD-L1抑制剂进行了生物学评价。其中，化合物L7在均相时间分辨荧光（HTRF）测定中表现出1.8 nM IC 50值，其效力比先导化合物BMS-1016强20倍。在表面等离子共振 (SPR) 测定中， L7与人 PD-L1 (hPD-L1) 结合， KD值为3.34 nM，但未显示与 hPD-1 的任何结合。在基于细胞的共培养测定中， L7阻断 PD-1/PD-L1 相互作用，EC 50值为 375 nM，而BMS-1016的 EC 50值为 2075 nM。此外，化合物L24 （ L7的酯前药）具有口服生物利用度，并且在同基因小鼠和PD-L1人源化小鼠的肿瘤模型中显示出显着的抗肿瘤作用。从机制上讲， L24可能通过促进抗肿瘤免疫而表现出显着的体内抗肿瘤作用。总之，这一系列苯并恶二唑 PD-L1 抑制剂为肿瘤免疫治
• Discovery of an Orally Bioavailable Gonadotropin-Releasing Hormone Receptor Antagonist
  作者：Seon-Mi Kim、Minhee Lee、So Young Lee、Euisun Park、Soo-Min Lee、Eun Jeong Kim、Min Young Han、Taekyung Yoo、Jihyae Ann、Suyoung Yoon、Jiyoun Lee、Jeewoo Lee

  DOI：10.1021/acs.jmedchem.6b01071

  日期：2016.10.13

  We developed a compound library for orally available gonadotropin-releasing hormone (GnRH) receptor antagonists that were based on a uracil scaffold. On the basis of in vitro activity and CYP inhibition profile, we selected 18a (SKI2496) for further in vivo studies. Compound 18a exhibited more selective antagonistic activity toward the human GnRH receptors over the GnRHRs in monkeys and rats, and this

  我们开发了基于尿嘧啶支架的口服促性腺激素释放激素（GnRH）受体拮抗剂的化合物库。根据体外活性和CYP抑制谱，我们选择18a（SKI2496）进行进一步的体内研究。与猴子和大鼠中的GnRHR相比，化合物18a对人GnRH受体具有更高的选择性拮抗活性，并且该化合物还对GnRH介导的信号传导途径具有抑制作用。与临床上最先进的化合物Elagolix相比，对18a的药代动力学和药效学评估显示出更高的生物利用度和优异的促性腺激素抑制活性。考虑到18a表现出对h GnRHRs的强效和选择性拮抗活性以及良好的药代动力学特征，我们认为18a可能代表口服激素治疗的有希望的候选者。
• 一类芳基二氟苄基醚类化合物、制备方法及用途
  申请人：中国科学院上海药物研究所

  公开号：CN110240587B

  公开（公告）日：2022-01-04

  本发明提供了一类芳基二氟苄基醚类化合物、制备方法及用途，具体地，本发明提供了一种如下式I所示的化合物，或其药学上可接受的盐，其外消旋体、R‑异构体、S‑异构体、可药用盐或它们的混合物。所述的化合物在PD‑1/PD‑L1竞争抑制实验中表现出比现有的PD‑1抑制化合物更好的结合抑制效果，因此可以用于制备治疗与PD‑1/PD‑L1结合通路相关的疾病的药物组合物。